Palmitoylethanolamide is recommended to use in a pure form. This is the conclusion of R.Kriek in a recent scietific paper on PEA and its various formulations. Pure PEA is available as PeaPure. Other formulations are available as Normast, Glialia en Pelvilen (among others).
In this recently published paper, R. Kriek discusses the disadvantages of various PEA formulations compared to pure PEA. He raises severe criticism related to the companies Epitech and Innovet (both companies producing PEA products such as Normast), and points out conflicts of interest of 2 authors of a recent paper. The paper was published in Inﬂammopharmacology, and both authors were working for the companies Epitech and Innovet. He states that it is thus of eminent importance to determine whether the statements in this paper have also taken into consideration the European guidelines for Good Clinical Practice and the codes of good scientiﬁc practices, and finds this not to be the case.
The author concludes and we quote:
Based on additional studies discussed in this commentary and in view of the effects of ultra-micronization on the parameters discussed, as well as the potential side-effects of additives such as excipients and herbal extracts added to the products cited in the article, the preference should be for the time being to treat patients with pure PEA without any of these additives.
Kriek shows that it is eminently clear that the article by Skaper et al. suffers from publication bias and selectivity that is contrary to good scientiﬁc practices.
1. Critical Paper:
Rutger Kriek. Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives. Inﬂammopharmacol february 2014; DOI 10.1007/s10787-014-0202-3
2. Original paper: Skaper SD1, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi: 10.1007/s10787-013-0191-7. Epub 2013 Nov 1.